Investigational Drug Information for Zibotentan
✉ Email this page to a colleague
What is the development status for investigational drug Zibotentan?
Zibotentan is an investigational drug.
There have been 27 clinical trials for Zibotentan.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2008.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are AstraZeneca, Cardiff University, and Papworth Hospital NHS Foundation Trust.
Summary for Zibotentan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 365 |
| WIPO Patent Applications | 195 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 3 (2008-01-01) |
| Vendors | 56 |
Recent Clinical Trials for Zibotentan
| Title | Sponsor | Phase |
|---|---|---|
| Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | AstraZeneca | Phase 3 |
| A Study to Assess the Effects of Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria | AstraZeneca | Phase 2 |
| A Study to Assess the Effects of Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria | University Medical Center Groningen | Phase 2 |
Clinical Trial Summary for Zibotentan
Top disease conditions for Zibotentan
Top clinical trial sponsors for Zibotentan
US Patents for Zibotentan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
